• The global cannabis market is expected to reach $33 billion by 2025, driven by legality and regulation within the market
• REZYFi is servicing the needs of both traditional and non-traditional consumers and businesses
• Company targets licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing
• REZYFi’s management team is leveraging its extensive industry experiences in real estate, finance and cannabis to pursue company objectives

The cannabis industry has experienced significant growth in recent years due to the expanding legalization and interest from venture capital firms. This growth is not only being seen in the United States but worldwide. Global cannabis sales are expected to increase from $13.4 billion in 2020 to $33 billion by 2025 (https://ibn.fm/GYkcJ). Legality and regulation are key forces that drive this market in the United States, but banking continues to be a challenge as cannabis companies cannot legally access traditional banking services. The Federal Reserve began raising interest rates in March 2022, which makes it even harder for cannabis companies to raise capital and fuel future growth. As a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses, REZYFi is targeting markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based and project-specific financings – like solar installations and real estate development projects. The company is positioned as one of the first cannabis mortgage bankers in the United States, an arena where most traditional lenders remain reticent to serve state-licensed cannabis companies. To overcome many of the challenges that the companies in the cannabis industry face, REZYFi plans to utilize its corporate strengths to facilitate growth, namely experience, a network of independent brokers, and proprietary technology. REZYFi’s experience comes from a management team with significant expertise that spans a wide range of real estate and financial sectors. This team also has extensive experience in the cannabis and hemp industries, which they will leverage as the company navigates the ever-changing cannabis industry landscape. Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers, allowing the company to train network members on its new service offerings. REZYFi believes this network is a vital asset as it moves forward in an industry where other firms are abandoning the cause. These strengths, coupled with REZYFi’s proprietary automated/machine learning technology, can shorten the loan processing timeframes and increase overall efficiencies. This allows REZYFi to operate its legacy business at staffing levels meaningfully below its competitors. REZYFi operates through its two wholly owned subsidiaries from its base of operations in Miami, Florida. The first, REZYFi Lending, primarily addresses the emerging real estate-related financing opportunities within the targeted industry. The second, ResMac Inc., is the company’s traditional mortgage origination, correspondent and servicing option. These subsidiaries are licensed to serve 34 states, and the company plans to expand to the remaining 16 states later in 2022. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Canadian clean energy and fertilizer innovator FuelPositive Corp. has launched its pre-sale application process for its long-awaited onsite, containerized green ammonia production system, capable of providing nitrogen fertilizer for a 2,000-acre farm
• The system is designed to deliver a solution to farmers’ dependence on uncertain supplies of fertilizer, as well as to eliminate the carbon emissions associated with the production of fertilizer
• In Europe, a number of large ammonia producers have severely reduced their supply as gas prices continue to soar as a consequence of Russia’s war on Ukraine and the industry’s dependence on Russian gas
• The reduction of European ammonia supply is expected to further exacerbate fears of food insecurity throughout nations already affected by declining agricultural production in Ukraine and Russia amid the war

The pending food insecurity crisis expected to arise from Russia’s war against Ukraine became more evident this summer as European fertilizer producers cut their output as a consequence of their dependence on Russian gas and Russia’s curbs on gas outflow to them because of the war’s economic strictures. An ocean away, Canadian clean energy and fertilizer solutions innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) announced in August that it has begun accepting pre-sale applications for its technological solution that addresses the very type of challenge being evidenced in Europe — it’s an onsite, modular system for producing green, hydrogen-dense ammonia that farmers and other potential end users can adopt to locally generate and manage fertilizer and fuel without reliance on the vagaries of the fertilizer and fuel supply chain. The containerized green ammonia production system created by FuelPositive is currently being built for a pilot project on the Manitoba crop farm of Tracy and Curtis Hiebert, who became the first pre-sales order customers in April when they committed to purchase a commercial system after testing is completed on the first demonstration system on their farm (https://ibn.fm/0Ue3A). “The FuelPositive system will give us stability. That’s what we like about it. It’s stabilizing the supply and stabilizing the price,” Curtis Hiebert stated in an August news release about the pre-sale program (https://ibn.fm/ZLQNj). Under FuelPositive’s pre-sale terms, interested farmers will use a dedicated email address to express interest in the system and will receive an introductory call to discuss their application, objectives and conditions on their farm, according to the news release. FuelPositive will then create a proposal tailored to their individual requirements to help customers see what will be required of them to produce their own green ammonia with the system. The customers can then enter a pre-sales agreement and secure a position in the production line-up with a deposit. After further planning arrangements, “a sales agreement will be considered to formalize the order,” the news release states. In Europe, ammonia fertilizer production has dropped to about 33% of previous levels, according to estimates by industry researcher CRU Group. Bloomberg reported that Norwegian producer Yara International ASA recently slashed its ammonia utilization, close on the heels of CF Industries’ announcement it will stop ammonia production at its last remaining plant in the United Kingdom. Lithuania’s top fertilizer company Achema AB will temporarily stop ammonia production in September, joining in cuts or cessation of output by producers in Hungary and Poland (https://ibn.fm/gePfa). “It is becoming very obvious that the European energy market is bust,” Fertilizers Europe spokesperson Lukas Pasterski told Bloomberg after wholesale fertilizer prices soared to multiyear highs on commodities insecurity, began to recover, then rose again as gas prices increased. “The system in place fails to handle the current situation,” Pasterski said. The initial base system price for FuelPositive’s system will be CA$950,000, although individual farm conditions may cause the actual price to vary as clients consider adding options or potentially deducting from the base system, according to the company. Once it is produced at scale efficiency, the company also will be able to offer customers greater savings over carbon-intensive ammonia costs. For more information on FuelPositive Corp., visit the company’s website at https://FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Correlate recently announced its letter of intent to acquire Vermont-based Aegis Renewable Energy and plans to use its deep regulatory knowledge, project fulfillment and operations and maintenance capabilities to deliver on and expand its project backlog in the region
• Correlate is at the forefront of creating industry-leading energy solutions and financing platforms for commercial and industrial sectors
• The portfolio for energy optimization is a $290 billion market, driving deep financial savings and energy efficiency across the commercial sector

Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean energy solutions provider for all of North America, is expanding its renewable energy market reach following its recent entry into the Northeast sector. The company announced its nonbinding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc. Aegis is a member of the Amicus Solar Cooperative Network, and a leading commercial, industrial and community solar company focused on project development and engineering, procurement and construction (“EPC”) services in the eastern United States. Completing the acquisition will provide Correlate with strategic abilities to capitalize on the Northeastern renewable energy market. The company intends to use Aegis’ deep regulatory knowledge, project fulfillment and operations and maintenance capabilities to deliver on and expand its project backlog in the region. “Upon completion of this key acquisition, Correlate will add to its highly experienced team and will bring proven success to the Northeast market as a leading renewable energy project developer while creating a compelling fit for expanding Correlate’s energy optimization platform,” CEO and President Todd Michaels stated (https://ibn.fm/2DJKW). The company is at the forefront of creating an industry-leading energy solution and financing platform for the commercial and industrial sectors. It sees tremendous market opportunities in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale to further its mission of advancing clean energy solutions critical in mitigating the effects of climate change. Correlate is accomplishing this through its two subsidiaries – Correlate, founded in 2015, and Solar Site Design, founded in 2013. The company sees opportunities to remove the friction between today’s legacy finance process and the needed clean energy upgrades to drive the necessary changes for the United States to reach its carbon goals by 2050. Commercial buildings are underperforming at every level of energy efficiency, consuming more than 35% of the generated electricity in the United States. Commercial buildings waste energy, emit too much carbon, and are costly for owners and occupants. However, retrofitting is not happening at the rate or scale necessary to meet clean energy goals. Correlate’s transparent and leading-edge model changes value delivery for facility owners and proven solution providers seeking scale. The company believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally. Correlate comprises collective experience that spans developing and financing renewable energy projects for many reputable brands and organizations nationwide, including Safeway, Frito Lay, Habitat for Humanity, and more. Completed projects include MGM Mandalay Resort in Las Vegas, the largest rooftop solar project west of the Mississippi; Albertson’s Safeway Portfolio California, with systems supporting more than 40% of usage for each store; Arizona State University in Phoenix, supporting 71% of campus output; and NFL stadiums in California, New York, Washington, and Massachusetts, creating a beacon of sustainability for stadiums around the world. The company is addressing a rapidly growing market encompassing over 5.9 million commercial buildings in the United States, according to the United States Energy Information Administration (https://ibn.fm/ghupu). Through its wholly owned subsidiaries, Correlate has access to an opportunity pipeline of over $100 million in commercial projects with more than $20 million in the awarded backlog. According to the Rocky Mountain Institute, the portfolio for energy optimization is a $290 billion market, driving deep financial savings and energy efficiency across the commercial sector (https://ibn.fm/MWLPj). For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.correlateinfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlateinfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• U.S. Department of Energy recently announced Biden administration plans to reduce geothermal system costs by 90% to $45 per megawatt hour by 2035
• GeoSolar’s SmartGreen(R) residential and commercial energy systems leverage solar and geothermal energy to dramatically lower or eliminate utility bills
• Additional SmartGreen(R) system customizations include tightening building envelope, insulation upgrades, LED lighting replacement, EV charging infrastructure

The U.S. Department of Energy (“DOE”) recently announced that the Biden administration plans to reduce geothermal system costs by 90% to $45 per megawatt hour by 2035 (https://nnw.fm/JJHUW). Increased awareness and mainstream adoption of the technology will likely benefit Colorado-based GeoSolar Technologies Inc., a leading climate technology company that develops and markets SmartGreen(R) – a residential and commercial energy system that taps into renewable energy sources to dramatically lower or eliminate utility bills. SmartGreen(R) revolutionizes how residential and commercial building owners heat, cool and power electric appliances and vehicles by leveraging innovative solar and geothermal technology. The company continues to validate SmartGreen(R) throughout multiple test markets with plans to market the system to millions of homes in both warm and cool climates across the United States. “The United States has a vast, geothermal energy resource lying right beneath our feet, and this program will make it economical to bring that power to American households and businesses,” said U.S. Secretary of Energy Jennifer M. Granholm. “DOE’s Enhanced Geothermal Shot will move geothermal technology from research and development to cost-effective commercial adoption, helping energy communities and workers transition to producing clean energy for the future.” According to the DOE, a small fraction of the country’s geothermal energy could affordably power over 40 million American homes, furthering the Biden administration’s goals to hit 100% pollution-free electricity by 2035 and net-zero emissions by 2050. The initiative also presents an opportunity to transition skilled workers from the fossil fuel industry to the “clean” energy sector. SmartGreen(R) accesses geothermal energy by drilling wells 300-400 feet below the earth and inserting high-density polyethylene pipe ground loops to extract power and disperse it throughout the home. In addition to leveraging the power of geothermal technology, the system provides an entire home makeover that includes photovoltaic (“PV”) solar systems, insulation upgrades, LED lighting, building envelope tightening, and other measures to conserve energy and improve efficiency. SmartGreen(R) will soon be accessible to millions of homes across the United States with 100% financing options, tax deductions and utility incentives. In addition, GeoSolar was recently qualified by the U.S. Securities and Exchange Commission to conduct a Regulation A+ capital raise. For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information on GeoSolar, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)
• The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls
• Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension
• Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers
• The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2)

Oral delivery remains the preferred route of administering drugs among cooperating and conscious patients. But some drugs do not have the desired physicochemical and pharmacokinetic characteristics that favor oral administration, an issue that is linked to poor bioavailability. This has often led to the use of other routes or prompted the administration of higher doses, with the latter causing toxicity concerns and risks tied to erratic and unpredictable responses. These challenges, coupled with the fact that more than 90% of therapeutic compounds are known to possess oral bioavailability limitations, have necessitated research that explores ways to enhance oral drug bioavailability (https://ibn.fm/xQ0vX). The research has been spearheaded by scholars and scientists as well as companies such as Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. A biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”), Lexaria developed the patented DehydraTECH(TM) drug delivery technology. Designed to be incorporated into the formulation and manufacturing process of existing or new topical and ingestible products, the technology works with existing physiological systems to facilitate enhanced and more rapid absorption of drugs into the bloodstream and cells. In fact, the company has evidenced, through in vivo, in vitro and pre-clinical testing, that DehydraTECH delivers more API at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (“CBD”), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD compound, for example, specifically targets the hypertension space; in the U.S., about 47% of adults, or 116 million people, have hypertension, with only about 24% having the condition under control (https://ibn.fm/ZEKeM), while globally, hypertension affects more than 1 billion people, or about 30% of the adult population (https://ibn.fm/sdKDi). A person is considered hypertensive if and when their systolic blood pressure (when the heart is beating) exceeds 130 mmHg or their diastolic blood pressure (when the heart is at rest) is greater than 80 mmHg or if they are on hypertension medication. This heightened pressure has several consequences, including the fact that it makes arteries less elastic, effectively damaging them. This damage, in turn, decreases the blood flow and oxygen to the heart, leading to heart disease. The decreased blood flow also increases the risk of stroke. In extreme cases, hypertension causes death. In 2020, over 670,000 people died from hypertension in the United States, according to the Centers for Disease Control (“CDC”). Globally, the World Health Organization (“WHO”) reports, 7.5 million people die from high blood pressure annually (https://ibn.fm/HCtyI). Unfortunately, some of these deaths occur among patients who may not have noticed any symptoms, leading to the recognition of hypertension as a “silent killer.” The good news? There are several approved blood pressure medications, with scores still under development or evaluation, including Lexaria’s DehydraTECH-CBD. In its human pre-clinical studies, Lexaria has shown that DehydraTECH delivers 317% more CBD to the bloodstream. Its HYPER-H21-1 study demonstrated that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure, particularly systolic pressure and especially in stage 2 hypertensive volunteers (those whose systolic pressure exceeds 140 mmHg). In addition, the company separately showed, through its HYPER-H21-2 study, that its drug candidate results in a 23% average reduction in overnight blood pressure and reduces arterial stiffness, while its HYPER-H21-3 study demonstrated attenuated pulmonary artery systolic pressure by -5 mmHg (https://ibn.fm/hCT43). Motivated by the positive results, Lexaria is marching toward filing an Investigational New Drug (“IND”) application, having already received confirmation from the U.S. Food and Drug Administration (“FDA”) that the agency had agreed with the company’s proposal to pursue the 505(b)(2) new drug application (“NDA”) abbreviated regulatory pathway (https://ibn.fm/NQaBK). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Freight Technologies is a technology company that develops solutions aimed at optimizing and automating the supply chain process
• The company’s solutions include Fr8App Platform, Fr8FMS, cloud-based Fr8TMS, Fr8Radar, Fr8Data, and Fr8Fleet
• Early this year, Freight Technologies unveiled Fr8Fleet, a technology solution for committed capacity planning, and announced it had secured its first contract for this product with Kimberly Clark de Mexico (“KCM”)
• The company recently reported an expanded relationship with KCM following an agreement to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S.

An insights report by multinational KPMG, entitled “The challenges of cross-border international trade,” lists logistics and supply chain as one of the major impediments businesses and suppliers must overcome to build effective and adequate cross-border trading capacity. “Tracking orders, determining liabilities for in-transit goods, and meeting promised delivery timeframes can all be more challenging in cross-border trade due to multicarrier handoffs and border delays,” the report underlines (https://ibn.fm/8qQPg). In addition to choosing between cross-border shipping or localized fulfillments – two core options to handle the complexity of international logistics – the report recommends the use of technology. “Technology can further simplify the challenges through multi carrier software platforms (also known as logistics control towers), which can select the most appropriate shipping partners and plan routes, prepare parcels for export, and pass on the exporter of record and liability elements to third parties,” the report explains. Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company that develops solutions aimed at optimizing and automating the supply chain process, has always understood the importance of integrating technology into logistics. Through its wholly owned subsidiary Freight App, Inc. (“Fr8App”), the company offers solutions such as the Fr8App Platform, a B2B cross-border shipping marketplace powered by artificial intelligence (“AI”) and machine learning; Fr8FMS, a solution that enables transportation companies and owners to handle their own fleet, thereby reducing operational costs; cloud-based Fr8TMS that allows users to manage fleet and request freight services on the marketplace; Fr8Radar; and Fr8Data. These technology solutions, the company holds, aim to contribute to its customers’ success by improving their efficiency and profitability. In a February 7 news release that further embodies this commitment, Fr8Tech unveiled Fr8Fleet, a technology solution that facilitates capacity planning by enabling corporate shippers to purchase fleet capacity over time – rather than on a trip-by-trip basis – in exchange for a flat fee (https://ibn.fm/g3FCv). According to CEO Javier Selgas’s comments on the new technology, Fr8Fleet affords participating carriers a steady stream of revenue while solving the need by shippers to secure capacity over time, particularly in the current tight market. As part of the unveiling, Fr8Tech also announced an agreement with the first corporate client for its Fr8Fleet technology, Kimberly-Clark de Mexico, S.A.B. de C.V. (“KCM”), a leading public company in Mexico that manufactures and commercializes branded consumer products. The initial arrangement was later expanded to include dedicated truck services on the Fr8App Platform for KCM as well as traditional spot services within domestic Mexico. Fr8Tech and KCM recently expanded their working relationship even further when the former announced that its Fr8App Platform for KCM would now support cross-border logistics for shipments from Mexico to the United States. As a result, Fr8Tech now supports three types of logistics services for the consumer products manufacturer (https://ibn.fm/RwjLn). “Pleased with the level of service and value KCM received from Fr8Fleet and domestic spot services, KCM logistics management chose the Fr8App platform to address their needs for the U.S./Mexico cross-border traffic,” commented Javier Selgas. “As KCM is one of the top consumer product manufacturers in North America, this important development validates Fr8Tech’s platform and services. KCM’s expanding relationship highlights our potential to increase business with existing customers as well as capture more transportation logistics trade from corporations of all sizes.” Fr8Tech aims to revolutionize logistics operations for brokers, carriers, and shippers by leveraging technology infrastructure to improve experiences and efficiency. The infrastructure combines everything in a single control center, optimizing logistics, making fleets more efficient, and reducing transportation costs. For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chain
• Flora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacity
• Flora is headquartered in Canada, but its strength lies in its Colombian-based cultivation operations centered in Colombia, one of the largest licensed outdoor operations in the world
• In recent years, Colombia’s government has been working to create a legalization framework for cannabis cultivation, processing and exportation to shake off its legacy of illegal drug trade violence

Canada-headquartered global cannabis brand-builder Flora Growth (NASDAQ: FLGC) is increasing the strength of its supply chain, centered in its 100-hectare (about 247-acre) cultivation facility located in the heart of Colombia’s green climate, by finalizing a distribution agreement with the Misak indigenous tribe’s pharmaceutical arm. “Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform for product distribution,” Flora Growth Chairman and CEO Luis Merchan stated in an August news release announcing the arrangement (https://ibn.fm/UAD84). “In return, Flora will be able to leverage the tribe’s unique regulatory positioning to expedite exports and increase global market penetration of Colombian cannabis goods.” Pharma Indigena Misak Manasr Sas, referred to simply as Manasr, is the tribe’s pharmaceutical enterprise, which in 2020 became the first native community business to receive a license from the national Ministry of Justice for producing legal cannabis for medicinal and scientific use, according to Google’s English translation of a local news report (https://ibn.fm/qA8aR). Flora Growth will assist the tribe with regulatory advice, as well as technical and business support and market promotion for Flora Growth-branded products, particularly as the tribe enters the international supply chain, as Merchan indicated. The agreement is for three years, with the potential to become a lasting, long-term collaboration. Prior to the June elections that established Colombia’s current national administration, the country underwent progressive drug policy changes in an effort to cast off its reputation as a haven for illegal drug trade and related organized crime violence. The normalization of the economy and legalization of cannabis commerce for medical purposes with regulated foreign exports have led to a revolutionary new energy for Colombia’s trades, which continues to be supported under the new administration. Flora’s Cosechemos facility provides cultivation, extraction and isolation operations at the city of Bucaramanga, supplemented by GMP-certified processing at a facility in the nation’s capital, Bogotá. Flora has established exports to Mexico and Spain and opening doors to the United Kingdom and the United States. The company recently reported its financial results for the first half of 2022, showing a 604 percent YOY growth in revenues as its design-led product profile and capital acquisitions gain market attention. The revenue growth was also a 117 percent increase over the second half of the previous year (https://ibn.fm/xz0Vw). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• First dose is administered as first-ever novel psilocybin analog enters clinical development
• Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin
• The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”)

Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants were dosed (https://ibn.fm/JXADp). “To commence dosing in our first-in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months,” said Cybin CEO Doug Drysdale. “Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients, and today we have moved one step closer. Through our rigorous preclinical work and ongoing clinical development of CYB003, we believe we have the potential to unlock the powerful benefits of psilocybin for the treatment of major depressive disorder (‘MDD’) without its well-known limitations.” The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration of effect, compared to oral psilocybin. CYB003 has the potential to reduce time in the clinic, which could allow more scalability and access for this treatment. As a randomized, double-blind, placebo-controlled study, the current phase 1/2a trial will evaluate individuals with moderate to severe MDD. Those who qualify for the study are between the ages of 21 and 55, have a verified diagnosis of MDD and are unsatisfied with their current prescribed medication and treatment. Participants will be allowed to remain on their current medication throughout the trial. “The high level of participant interest in our study serves to validate the significant unmet need for alternative and better treatment options to improve mental health conditions,” said Drysdale. “We expect that this phase 1/2a trial will provide valuable insights and data. These findings will be critical in establishing a safe and efficacious treatment profile for CYB003 so we can continue to progress our mission to help revolutionize the treatment landscape for people suffering from depression.” Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization
• QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations
• Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam

With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “The overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975. Overall cancer incidence rates increased an average of 1% per year from 1997 to 2018,” reports Children’s Cancer Cause, the leading national advocacy organization for children’s cancer (https://ibn.fm/foz9V). According to Children’s Cancer Cause, in 2022 an estimated 10,470 children (from birth to 14 years) and 5,480 adolescents (aged 15 to 19 years) will be diagnosed with cancer. “It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and treatments, of this, 45% will go undiagnosed and 11.1 million will die if no further investments in interventions are made. The vast majority, almost 85%, will be concentrated in developing countries.” The group went on to note that cancer in children and young adults is different from cancer that develops in adults. “Some of the unwanted side effects of cancer treatments cause more harm to children than they do to adults,” the report states. “This is because children’s bodies are still growing and developing, so cancer and its treatment are more likely to affect developing organs. “More than 95% of childhood cancer survivors will have a significant health-related issue by the time they are 45 years of age,” the report continued. “These health-related issues are side effects of either the cancer or, more commonly, the result of its treatment: one-third will suffer severe and chronic side effects, one-third will suffer moderate to severe health problems, and one-third will suffer slight to moderate side effects.” QSAM Biosciences is working to make a difference in this space, as well as in the adult cancer sector. The company is developing “targeted therapeutic radiopharmaceuticals as safer and more efficacious alternatives to current treatment modalities to address large unmet medical needs and underserved patient populations” (https://ibn.fm/gE7c6). With that in mind, QSAM is focused on creating a pipeline of novel radiotherapeutics to serve multiple indications. The company’s lead product, CycloSam(R), is a clinical-stage, bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “CycloSam delivers the beta-emitting radioisotope, Samarium-153, to areas of rapid bone formation through a superior chelant, DOTMP, emitting a potent yet controlled dose of radiation treatment directly to the tumor environment while minimizing radiation exposure to healthy tissue,” the company reports. “The results we seek are halting or regressing primary and metastatic tumors in bone for both children and adults. . . . CycloSam is the next generation of an already FDA-approved drug, with patented improvements to increase efficacy and utility, reduce toxicity, and streamline production.” For more information, visit the company’s website at www.QSAMbio.com. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM

• Traditional natural gas extraction pollutes air, contaminates water, disturbs landscape
• Renewable natural gas is derived from organic sources, compatible with existing traditional natural gas pipeline grid
• EverGen operates projects in British Columbia and Alberta, recently acquired 50 percent stake in Ontario-based Project Radius located in Eastern Canada
• Company recently signed $31 million senior term loan to help fund RNG facility upgrades and expand projects

Traditional pipeline natural gas is extracted by vertical or horizontal drilling, and hydraulic fracturing. Well-drilling activities pollute the air, disturb lands, and contaminate water, while hydraulic fracturing – widely referred to as “fracking” – has similar consequences in addition to causing earthquakes (https://ibn.fm/ldZri). In contrast, renewable natural gas (“RNG”) is derived from organic sources while still being compatible with North America’s existing gas pipeline grid. EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) is leading the movement in Canada by acquiring, developing, building, and operating a portfolio of RNG, waste-to-energy, and related infrastructure projects. “Renewable natural gas, in Canada and the U.S., is a market that’s really starting to pick up steam,” said EverGen’s CEO and Co-Founder Chase Edgelow on a recent episode of IBN’s Bell2Bell Podcast (https://ibn.fm/fJLS8). “The gas utilities on both sides of Canada – the West Coast and Quebec – have both set targets of 15-20 percent of their volume to come from RNG or renewable products by 2030.” As part of its national expansion, EverGen recently acquired a 50 percent interest in Project Radius, a portfolio of RNG development projects in Ontario that include three RNG projects collectively capable of producing approximately 1.7 million RNG GJ/year. Scheduled to be constructed throughout 2023 and 2024, the acquisition provides EverGen with a foothold in the East that the company can use to participate in the consolidation and growth of the Canadian RNG industry. “Working alongside Northeast to advance the projects, EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually,” said Edgelow (https://ibn.fm/lSObZ). “Ontario has an abundant amount of excess organic feedstock, and as a leader in the RNG industry, EverGen can develop the sustainable infrastructure that contributes to carbon-negative energy production and the greening of the province.” To support its West coast projects, EverGen recently signed a $31 million senior term loan to help fund RNG facility upgrades and expand projects. “We’re fully funded to take our core expansion projects from where they are today (we’re cash flow positive today) to north of $13 million in EBITDA from those core assets, which are located in British Columbia and Alberta now with our acquisition of GrowTEC,” said Edgelow in comments referring to the company’s acquisition of the Alberta-based renewable natural gas facility. “When you add it all together, we’ve got a business capable of delivering $30 million of EBITDA from the portfolio that we have in front of us, and we see 25+ projects in Canada that could deliver 4x growth beyond that. There’s a tremendous amount of opportunity in this space right now.” Based in Vancouver, British Columbia, EverGen is an established independent renewable energy producer that is committed to combating climate change and contributing to a sustainable future. The company currently focuses on Canada with the long-term goal of developing RNG infrastructure throughout North America and beyond. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF